Research

Adherence

Systematic screening for NAFLD is not recommended by the AASLD even in high-risk populations due to lack of effective drug treatments, cost-effectiveness concerns, and unclear long-term benefits.

In the US, you likely won't be systematically screened for NAFLD even if you have diabetes, because there are no approved drugs for it yet. Focus on managing your metabolic health instead.

GoodRefutesHIGH confidence
AASLD currently recommends against screening even in high-risk populations because of the lack of effective drug treatment, cost-effectiveness analysis, and unclear long-term benefits to screening.
Yumi Ando et al. · Clinical Liver Disease · 2021

Why this rating

Based on guideline consensus and cost-effectiveness analysis references.

Source

Nonalcoholic Fatty Liver Disease and Recent Guideline Updates

Yumi Ando et al. · Clinical Liver Disease · 2021

narrative_reviewCited 167×
Read the paper

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →